Related Experiment Video

Updated: Oct 25, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K

Targeted radioactive therapy for prostate cancer - Authors' reply

Michael S Hofman1, Shahneen Sandhu1, Roslyn J Francis2

  • 1Centre for Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, 3000 VIC, Australia.

Lancet (London, England)
|August 8, 2021
PubMed
Summary

No abstract available in PubMed .

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K

Related Experiment Videos

Last Updated: Oct 25, 2025

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.6K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

10.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

Articles linked to this work by shared authors, journal, and citation graph.

A Phase 2, Open-Label, Randomized Controlled Trial Evaluating Safety and Efficacy of Dose-Intensified Versus Standard Dosing Regimens of [177Lu]Lu-PSMA-597 in mCRPC (OPTIMAL-PSMA).

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026

Dose-intensified PSMA Radioligand Therapy: The Rationale Behind the OPTIMAL-PSMA Trial.

European urology focus·2026

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026

Diagnosis and Staging of Patients with Prostate Cancer: Report from the 2025 Advanced Prostate Cancer Consensus Conference (APCCC) Diagnostics.

European urology·2026

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026

Dynamic Changes in Tumor Burden in Patients Undergoing PSMA RLT.

European urology oncology·2026

Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.

Lancet (London, England)·2026

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Switch to once-weekly, single-tablet islatravir-lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial.

Lancet (London, England)·2026

[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial.

Lancet (London, England)·2026

Microenvironment-Responsive Nanoparticles Enhance Rheumatoid Arthritis Treatment by Inducing Apoptosis in Inflammatory Macrophages and Fibroblast-like Synoviocytes.

ACS applied materials & interfaces·2026

Radiation safety and cancer risks in pediatric computed tomography: a systematic review of large-scale cohort studies.

Frontiers in pediatrics·2026

Adaptation of wild-type rabies virus on vaccine producing cell line and its quantification by peroxidase-based immunostaining.

Archives of virology·2026

Simulation-free vaginal cuff brachytherapy for high-intermediate risk endometrial cancer.

Brachytherapy·2026

Effects of different types of ionizing radiation on DNA from the perspective of medicine and planned piloted interplanetary flights.

Casopis lekaru ceskych·2026

Time toxicity in patients receiving brachytherapy and hormonal therapy for recurrent prostate cancer: a cohort study.

BMJ supportive & palliative care·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us